Instrument Fundamentals
Date | Close | Change | Change (%) | Open | High | Low |
---|
News
Teva-Sanofi upbeat on ‘best-in-class’ duvakitug bowel disease data | BioWorld
Bayer's high-dose eye treatment aflibercept shows positive late-stage trial results By Investing.com
Bayer Consumer Health champions green transportation - Chinadaily.com.cn
Kyorin in-licenses Bayer’s phase II sleep apnea drug for €85M+ | BioWorld
KYORIN Strikes Deal with Bayer for OSA Treatment | Markets Insider
BridgeBio Pharma Inc (BBIO) Receives Positive CHMP Opinion for Acoramidis in EU
Bayer Gets EU Backing for Heart Drug, Easing Patent Concerns
BridgeBio Pharma Announces CHMP's Positive Recommendation Of Acoramidis - Quick Facts
Bayer Bets on Barcelona with a New R&D Area in Health
Other news to note for Dec. 12, 2024 | BioWorld
Red mud generation trend across major countries, 2018 to 2023 | SMM
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU | Morningstar
HEALTHCARE: Bayer (BAYNGR: Baa2 neg / BBB / BBB): Antonou Roundup mistrial
'Vague' Product Testing Allegations Sink Benzene Class Action
Pragmatic trade policies & focus on quality essential to create innovative drugs ecosystem in India: Experts
FDA Accepts Cytokinetics' Application for Cardiovascular Drug - December 3, 2024 - Zacks.com
OneMedNet Announces Exciting New Collaboration with Bayer's AI Innovation Platform to Help Accelerate Healthcare AI Development | The Manila Times
OneMedNet and Bayer team up for AI medical imaging By Investing.com
Lack of protective gear exposing farmers to chemicals - Beyer
Lack of protective gear exposing farmers to chemicals - Bayer
Another Option for Weed Control
Calls for Canada to ban bee-killing pesticides after damning CNO investigation | Canada's National Observer: Climate News
CREDIT SUPPLY: Heimstaden Bostad (HEIBOS: BB neg/BB neg): New Perp FV 6.70%
Dhanuka in pact with Bayer to acquire two active ingredients - The Hindu BusinessLine
BridgeBio's SWOT analysis: genetic disease fighter's stock faces pivotal moment By Investing.com
Dhanuka Agritech to acquire Bayer's crop protection products | Capital Market News - Business Standard
Non-exudative OCT findings in neovascular AMD
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
Dhanuka Agritech jumps on inking pact with Bayer AG to acquire crop protection active ingredients
Dhanuka Agritech acquires two key ingredients from Bayer AG to expand global footprint
5 Stocks With the Largest Fair Value Estimate Cuts After Q3 Earnings | Morningstar
FDA Accepts Bayer's Application for Label Expansion of Nubeqa - November 22, 2024 - Zacks.com
Bayer gains exclusive licence for heart drug in Japan
U.S. FDA Accepts Supplemental New Drug Application for NUBEQA® (darolutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer | Morningstar
UBS Reaffirms Their Hold Rating on Bayer (0P6S)
Pilot and feasibility studies in ophthalmology: fundamental keys to success
Mindsprint keen to focus on food and agriculture sectors, says its CEO - The Hindu BusinessLine
Pivot Bio Names Jason Hoag Head of North American Commercial Distribution | Morningstar
Cytokinetics, Bayer ink pact to develop HCM investigational drug Aficamten in Japan, ETPharma
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan - November 20, 2024 - Zacks.com
Bayer recalls Yaz Plus contraceptives due to a quality issue | SAnews
Bayer AG shares target cut to EUR25 from EUR29 by CFRA By Investing.com
Goldman Sachs maintains Neutral on Cytokinetics, $60 target By Investing.com
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan
How Bayer, Evonik & Henkel can Reduce Supply Chain Emissions
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan | The Manila Times
Bayer acquires rights to Cytokinetics' heart drug in Japan By Reuters